Overview

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Status:
RECRUITING
Trial end date:
2031-08-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Geritol
Magnesium Sulfate
Succimer